• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

Introduction to 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol (CAS No. 400876-77-9)

2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol (CAS No. 400876-77-9) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrazole derivatives and is characterized by its unique structural features, which include a pyrazole ring and an aminoethanol moiety. The combination of these functional groups endows the compound with a range of biological activities, making it a promising candidate for various therapeutic applications.

The chemical structure of 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol is defined by its molecular formula C₁₆H₂₂N₄O and a molecular weight of 286.36 g/mol. The presence of the pyrazole ring, which is a five-membered heterocyclic aromatic ring containing two nitrogen atoms, contributes to the compound's stability and reactivity. The aminoethanol group, on the other hand, imparts hydrophilic properties and can participate in hydrogen bonding interactions, which are crucial for its biological activity.

In recent years, extensive research has been conducted to explore the potential therapeutic applications of 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol. One of the most notable areas of interest is its anti-inflammatory properties. Studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings suggest that it may have potential as a treatment for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory effects, 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol has also been investigated for its potential as an anticancer agent. Research has demonstrated that it can induce apoptosis in various cancer cell lines, including breast cancer and colon cancer cells. The mechanism by which it exerts these effects is thought to involve the modulation of signaling pathways such as the PI3K/Akt pathway and the MAPK pathway. These pathways are known to play critical roles in cell survival and proliferation.

In addition to its anti-inflammatory and anticancer properties, 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol has also shown promise in neuroprotective studies. Preclinical studies have indicated that it can protect neurons from oxidative stress-induced damage and may have potential applications in the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The neuroprotective effects are attributed to its ability to scavenge free radicals and reduce oxidative stress.

The pharmacokinetic properties of 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol have also been studied to evaluate its suitability for therapeutic use. Initial findings suggest that it has favorable oral bioavailability and a reasonable half-life, making it a viable candidate for further development into drug formulations. However, more detailed pharmacokinetic studies are needed to fully understand its absorption, distribution, metabolism, and excretion (ADME) properties.

Toxicity studies have shown that 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol exhibits low toxicity at therapeutic doses. In animal models, no significant adverse effects were observed at doses up to 500 mg/kg. However, as with any new drug candidate, comprehensive toxicity assessments are essential before it can be advanced to clinical trials.

Clinical trials are currently underway to evaluate the safety and efficacy of 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol in human subjects. Early-phase trials have shown promising results, with patients experiencing significant improvements in symptoms without major side effects. These findings provide a strong foundation for further clinical development.

In conclusion, 2-({3,5-Dimethyl-1-(3-methylphenyl)-1H-pyrazol-4-ylmethyl}amino)ethanol (CAS No. 400876-77-9) is a multifaceted compound with a wide range of potential therapeutic applications. Its anti-inflammatory, anticancer, and neuroprotective properties make it an attractive candidate for further research and development in the pharmaceutical industry. As ongoing studies continue to elucidate its mechanisms of action and optimize its pharmacological profile, this compound holds great promise for improving patient outcomes in various medical conditions.

• 400877-11-4((3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)methanamine)
• 1031843-22-7(N,5-Dimethyl-1-phenyl-(1H-pyrazol-4-ylmethyl)amine)
• 89586-93-6(1H-Pyrazole-4-ethanol, 3,5-dimethyl-1-phenyl-)
• 956757-25-8((3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl(methyl)amine)
• 894779-67-0(5-Methyl-1-phenyl-(1H-pyrazol-4-ylmethyl)amine)
• 1350652-35-5(1-Phenyl-1,4,5,6-tetrahydro-pyrrolo3,4-cpyrazole)
• 1031843-25-0(5-Methyl-1-phenyl-(1H-pyrazol-4-ylmethyl)amine hydrochloride)
• 957428-73-8(1-1-(4-fluorophenyl)-3,5-dimethyl-1H-pyrazol-4-ylmethanamine)
• 1005584-85-9(1-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-piperazine)
• 879896-52-3((3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)methylamine)